Cochrane Evidence Synthesis and Methods ►

Prophylactic treatment with monoclonal antibodies targeting the CGRP pathway for migraine prevention

This is a protocol for a Cochrane Review (intervention). The objectives are as follows:

To assess the effects of monoclonal antibodies targeting the CGRP pathway compared with placebo or active treatments in preventing or reducing the symptoms of migraine attacks in adult and paediatric patients.

This is a protocol.

Health topics:

Neurology > Headache & migraine > Prevention

Pain & anaesthesia > Chronic non-cancer pain > Prevention

Published:

5 July 2023

Authors:

Oteri V, Douba Z, Rayi A, Letteri F, Moscote-Salazar LR, Pacheco-Barrios K, Celani MG, Eusebi P, Ricci S, Sacco S, Cantisani TA

See the full Review on

the Cochrane Library

►

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Oteri V, Douba Z, Rayi A, Letteri F, Moscote-Salazar LR, Pacheco-Barrios K, Celani MG, Eusebi P, Ricci S, Sacco S, Cantisani TA. Prophylactic treatment with monoclonal antibodies targeting the CGRP pathway for migraine prevention (Protocol). Cochrane Database of Systematic Reviews 2023, Issue 7. Art. No.: CD015505. DOI: 10.1002/14651858.CD015505.